Enterprise Value
59.11M
Cash
84.39M
Avg Qtr Burn
-18.66M
Short % of Float
0.88%
Insider Ownership
12.13%
Institutional Own.
28.42%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
UCART22 Details Acute lymphoblastic leukemia, Rare genetic disease, Cancer, B-cell acute lymphoblastic leukemia | Phase 1/2 Data readout | |
UCART20x22 Details Cancer, Non-Hodgkin lymphoma | Phase 1/2 Data readout | |
UCART123 Details Cancer, Relapsed/refractory acute myeloid leukemia | Phase 1 Data readout | |
ALLO-501 Details Non-Hodgkin lymphoma, Cancer | Failed Discontinued | |
ALLO-715 Details Cancer, Multiple myeloma | Failed Discontinued | |
UCARTCS1 Details Cancer, Multiple myeloma, Menkes Disease | Failed Discontinued | |
UCART19 (anti-CD19) Details Cancer, Multiple myeloma, Acute lymphoblastic leukemia | Failed Discontinued |